TP53 and lymphoma: The use of the bead-array based technology in patients with lymphoma [23], colorectal cancer [44] and glioblastoma multiforme [45] have shown that similar to what we observed in ALL, a frequent and simultaneous methylation of some of these genes is a frequent event in other tumors indicating that in addition to classical mutations and deletions of TP53, we should take into account indirect inactivation of TP53 in other types of human cancers.